Previous clinical trial studies such as JAVELIN Gastric 300 (Bang et al., 2018), KEYNOTE-061 (Shitara et al., 2018), and KEYNOTE-062 (Shitara et al., 2020) have shown that PD-1/PD-L1 inhibitors do not have significant advantages over conventional chemotherapy in the treatment of GC. The gene discussed is PDCD1; the disease is gastric cancer.